Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tenaya Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TNYA
Nasdaq
8731
https://www.tenayatherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tenaya Therapeutics Inc
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
- May 2nd, 2024 9:00 pm
Institutions own 33% of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) shares but private equity firms control 44% of the company
- Apr 14th, 2024 1:50 pm
20 Countries with the Highest Heart Disease Deaths Per Capita
- Mar 26th, 2024 11:19 am
Tenaya Therapeutics Inc Reports Full Year and Q4 2023 Financial Results
- Mar 20th, 2024 9:32 am
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Mar 18th, 2024 8:05 pm
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
- Mar 18th, 2024 12:30 pm
14 Stocks With Heavy Insider Buying In 2024
- Feb 29th, 2024 8:02 am
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
- Feb 27th, 2024 9:30 pm
Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?
- Feb 26th, 2024 2:55 pm
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications
- Feb 26th, 2024 1:30 pm
Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet
- Feb 9th, 2024 2:55 pm
Tenaya Therapeutics Announces Pricing of Underwritten Offering
- Feb 8th, 2024 1:00 pm
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why
- Jan 26th, 2024 5:00 pm
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 1:30 pm
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference
- Nov 21st, 2023 9:30 pm
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 8th, 2023 9:05 pm
Institutional investors have a lot riding on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) with 38% ownership
- Nov 6th, 2023 1:20 pm
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
- Oct 26th, 2023 12:30 pm
We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth Carefully
- Oct 10th, 2023 11:52 am
Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting
- Oct 9th, 2023 12:30 pm
Scroll